2022
DOI: 10.1016/j.biopha.2021.112544
|View full text |Cite
|
Sign up to set email alerts
|

The expression and function of miR-622 in a variety of tumors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

3
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 10 publications
(6 citation statements)
references
References 59 publications
3
3
0
Order By: Relevance
“…5) remains underexplored. For miR-622, the literature also reports that this retro-miR can act as both a tumor suppressor and an onco-miR in several cancers, such as breast cancer, glioma, colorectal cancer, hepatocellular carcinoma (HCC), lung cancer, gastric cancer (GC), melanoma, ovarian carcinoma, prostate cancer, and pancreatic cancer [40], which is in agreement with our results (Fig. 5).…”
Section: Discussionsupporting
confidence: 93%
“…5) remains underexplored. For miR-622, the literature also reports that this retro-miR can act as both a tumor suppressor and an onco-miR in several cancers, such as breast cancer, glioma, colorectal cancer, hepatocellular carcinoma (HCC), lung cancer, gastric cancer (GC), melanoma, ovarian carcinoma, prostate cancer, and pancreatic cancer [40], which is in agreement with our results (Fig. 5).…”
Section: Discussionsupporting
confidence: 93%
“…5) remains underexplored. For miR-622, the literature also reports that this retro-miR can act as both a tumor suppressor and an onco-miR in several cancers, such as breast cancer, glioma, colorectal cancer, hepatocellular carcinoma (HCC), lung cancer, gastric cancer (GC), melanoma, ovarian carcinoma, prostate cancer, and pancreatic cancer [43], which is in agreement with our results (Fig. 5).…”
Section: Discussionsupporting
confidence: 93%
“…However, the importance of this retro-miR in other tumors (Figure 5) remains underexplored. For miR-622, the literature also reports that this retro-miR can act as both a tumor suppressor or an onco-miR in several cancers, such as breast cancer, glioma, CRC, hepatocellular carcinoma (HCC), lung cancer, gastric cancer (GC), melanoma, ovarian carcinoma, prostatic cancer, and pancreatic cancer [40], in agreement with our expression results (Figure 5). Like the other two retro-miRs, the literature reports that miR-492 acts as both a tumor suppressor and an oncogene.…”
Section: Discussionsupporting
confidence: 92%